GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Concord Biotech Ltd (BOM:543960) » Definitions » Price-to-Owner-Earnings

Concord Biotech (BOM:543960) Price-to-Owner-Earnings : 99.35 (As of Jun. 01, 2025)


View and export this data going back to 2023. Start your Free Trial

What is Concord Biotech Price-to-Owner-Earnings?

As of today (2025-06-01), Concord Biotech's share price is ₹1746.55. Concord Biotech's Owner Earnings per Share (TTM) ended in Mar. 2025 was ₹17.58. It's Price-to-Owner-Earnings for today is 99.35.


The historical rank and industry rank for Concord Biotech's Price-to-Owner-Earnings or its related term are showing as below:

BOM:543960' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 77.85   Med: 83.49   Max: 99.35
Current: 99.35

During the past 6 years, the highest Price-to-Owner-Earnings of Concord Biotech was 99.35. The lowest was 77.85. And the median was 83.49.


BOM:543960's Price-to-Owner-Earnings is ranked worse than
82.58% of 178 companies
in the Biotechnology industry
Industry Median: 28.765 vs BOM:543960: 99.35

As of today (2025-06-01), Concord Biotech's share price is ₹1746.55. Concord Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was ₹35.52. Therefore, Concord Biotech's PE Ratio (TTM) for today is 49.17.

As of today (2025-06-01), Concord Biotech's share price is ₹1746.55. Concord Biotech's EPS without NRI for the trailing twelve months (TTM) ended in was ₹35.52. Therefore, Concord Biotech's PE Ratio without NRI for today is 49.17.

During the past 6 years, Concord Biotech's highest PE Ratio without NRI was 86.76. The lowest was 38.51. And the median was 52.08.


Concord Biotech Price-to-Owner-Earnings Historical Data

The historical data trend for Concord Biotech's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Concord Biotech Price-to-Owner-Earnings Chart

Concord Biotech Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Price-to-Owner-Earnings
Get a 7-Day Free Trial - - - 82.77 95.36

Concord Biotech Quarterly Data
Mar20 Mar21 Mar22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 82.77 - - - 95.36

Competitive Comparison of Concord Biotech's Price-to-Owner-Earnings

For the Biotechnology subindustry, Concord Biotech's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Concord Biotech's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Concord Biotech's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Concord Biotech's Price-to-Owner-Earnings falls into.


;
;

Concord Biotech Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Concord Biotech's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=1746.55/17.58
=99.35

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Concord Biotech  (BOM:543960) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Concord Biotech Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Concord Biotech's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Concord Biotech Business Description

Traded in Other Exchanges
Address
Iscon Cross Road, S.G. Highway, B-1601-1602, B-Wing, Mondeal Heights, Ahmedabad, GJ, IND, 380015
Concord Biotech Ltd is a research and development-driven biopharma company that manufactures Active Pharmaceutical Ingredients (API) through fermentation and semi-synthetic process and finished formulations. It is mainly engaged in the business of manufacturing and trading in pharmaceutical products.

Concord Biotech Headlines

No Headlines